'HHS Calls For Moving Marijuana To Lower-Risk US Drug Category' - Bloomberg News
Portfolio Pulse from Happy Mohamed
US health officials are recommending that marijuana be reclassified as a Schedule III drug under the Controlled Substances Act, which would mark a shift from its current status as a Schedule I substance. This move could potentially expand the cannabis market.
August 30, 2023 | 4:19 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
The reclassification of marijuana could potentially expand the cannabis market, which may positively impact Aurora Cannabis Inc.
As a company in the cannabis industry, Aurora Cannabis Inc. stands to benefit from the potential expansion of the cannabis market due to the reclassification of marijuana.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The reclassification of marijuana could potentially expand the cannabis market, which may positively impact Canopy Growth Corporation.
As a company in the cannabis industry, Canopy Growth Corporation stands to benefit from the potential expansion of the cannabis market due to the reclassification of marijuana.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The reclassification of marijuana could potentially expand the cannabis market, which may positively impact Cronos Group Inc.
As a company in the cannabis industry, Cronos Group Inc. stands to benefit from the potential expansion of the cannabis market due to the reclassification of marijuana.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
The reclassification of marijuana could potentially expand the cannabis market, which may positively impact Tilray Inc.
As a company in the cannabis industry, Tilray Inc. stands to benefit from the potential expansion of the cannabis market due to the reclassification of marijuana.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80